S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
NASDAQ:MNPR

Monopar Therapeutics (MNPR) Stock Price, News & Analysis

$0.74
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$0.70
$0.80
50-Day Range
$0.31
$1.35
52-Week Range
$0.27
$1.75
Volume
142,611 shs
Average Volume
559,607 shs
Market Capitalization
$10.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Monopar Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
171.4% Upside
$2.00 Price Target
Short Interest
Healthy
3.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.42mentions of Monopar Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.67) to ($0.68) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.73 out of 5 stars

Medical Sector

408th out of 939 stocks

Pharmaceutical Preparations Industry

189th out of 431 stocks

MNPR stock logo

About Monopar Therapeutics Stock (NASDAQ:MNPR)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

MNPR Stock Price History

MNPR Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Monopar Therapeutics Inc
Dow Surges Over 150 Points; AerCap Posts Upbeat Earnings
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Kyverna Therapeutics Inc
Monopar Therapeutics Inc. (MNPR)
See More Headlines
Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/27/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MNPR
Fax
N/A
Employees
11
Year Founded
2014

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+171.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.78 per share

Miscellaneous

Free Float
8,682,000
Market Cap
$10.96 million
Optionable
Not Optionable
Beta
1.21

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Chandler D. Robinson M.B.A. (Age 40)
    M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director
    Comp: $708.12k
  • Ms. Kim R. Tsuchimoto CPA (Age 61)
    CFO, Secretary, Treasurer & Director
    Comp: $350.55k
  • Mr. Andrew J. Cittadine M.B.A. (Age 52)
    Chief Operating Officer
    Comp: $390.41k
  • Dr. Patrice P. Rioux M.D. (Age 73)
    Ph.D., Acting Chief Medical Officer

MNPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Monopar Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MNPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MNPR, but not buy additional shares or sell existing shares.
View MNPR analyst ratings
or view top-rated stocks.

What is Monopar Therapeutics' stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Monopar Therapeutics' stock. Their MNPR share price targets range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 171.4% from the stock's current price.
View analysts price targets for MNPR
or view top-rated stocks among Wall Street analysts.

How have MNPR shares performed in 2024?

Monopar Therapeutics' stock was trading at $0.3402 at the beginning of 2024. Since then, MNPR stock has increased by 116.6% and is now trading at $0.7370.
View the best growth stocks for 2024 here
.

Are investors shorting Monopar Therapeutics?

Monopar Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 229,600 shares, a decline of 73.0% from the February 29th total of 848,800 shares. Based on an average daily volume of 5,220,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 3.6% of the shares of the company are sold short.
View Monopar Therapeutics' Short Interest
.

When is Monopar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our MNPR earnings forecast
.

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02.

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST).

When did Monopar Therapeutics IPO?

Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager.

How do I buy shares of Monopar Therapeutics?

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Monopar Therapeutics have any subsidiaries?
The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.
Read More
This page (NASDAQ:MNPR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners